PMID- 21273611
OWN - NLM
STAT- MEDLINE
DCOM- 20110317
LR  - 20181201
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 31
IP  - 1
DP  - 2011 Jan
TI  - C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by 
      Erlotinib.
PG  - 281-5
AB  - BACKGROUND: The clinical impact of c-erbB-3 has seldom been assessed in patients 
      with non small cell lung cancer (NSCLC). PATIENTS AND METHODS: Forty-three NSCLC 
      patients treated by erlotinib for c-erbB-3 and EGFR expression were investigated 
      by immunohistochemistry analysis. RESULTS: Two partial responses, one minor 
      response, two stable diseases and twenty progressive diseases were observed at 
      the first evaluation. Seventeen patients died before evaluation. Median EGFR 
      expression was 70% of the cancer cells. Forty-two percent of the tumours 
      co-expressed c-erbB-3 and EGFR without any difference according to histology or 
      disease stage. There was no correlation between c-erbB-3 and EGFR expression. 
      Median survival time was 2.6 months and the six months survival rate was 21%. 
      There was no detectable impact of EGFR (p=0.94) or c-erbB-3 (p=0.93) expression 
      on survival. CONCLUSION: In this small particular cohort of NSCLC patients 
      receiving salvage therapy with erlotinib, there was no correlation between 
      c-erbB-3 expression and clinical parameters, nor between cerbB-3/EGFR expression 
      and outcome.
FAU - CsToth, Ingrid
AU  - CsToth I
AD  - Departement d'Oncologie Thoracique et Soins Intensifs et Data Centre,Institut 
      Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.
FAU - Anthoine, Geraldine
AU  - Anthoine G
FAU - Berghmans, Thierry
AU  - Berghmans T
FAU - Mascaux, Celine
AU  - Mascaux C
FAU - Paesmans, Marianne
AU  - Paesmans M
FAU - Sculier, Jean-Paul
AU  - Sculier JP
FAU - Meert, Anne-Pascale
AU  - Meert AP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-3)
SB  - IM
MH  - Adenocarcinoma/drug therapy/metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology
MH  - Carcinoma, Squamous Cell/drug therapy/metabolism/pathology
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Erlotinib Hydrochloride
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Lung Neoplasms/*drug therapy/metabolism/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Quinazolines/*therapeutic use
MH  - Receptor, ErbB-3/*metabolism
MH  - Survival Rate
EDAT- 2011/01/29 06:00
MHDA- 2011/03/18 06:00
CRDT- 2011/01/29 06:00
PHST- 2011/01/29 06:00 [entrez]
PHST- 2011/01/29 06:00 [pubmed]
PHST- 2011/03/18 06:00 [medline]
AID - 31/1/281 [pii]
PST - ppublish
SO  - Anticancer Res. 2011 Jan;31(1):281-5.